LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
Cidara Therapeutics Inc.
Headquarters:
San Diego, CA, United States
Website:
http://www.cidara.com
Year Founded:
2012
Status:
Public
Industry Sector:
HealthTechnology
CEO:
Jeffrey L. Stein, PhD
Number Of Employees:
38
Enterprise Value:
$-21,922,919
PE Ratio:
-0.67
Exchange/Ticker 1:
NASDAQ:CDTX
Exchange/Ticker 2:
N/A
Latest Market Cap:
$252,003,200
BioCentury
|
May 1, 2025
Management Tracks
Augustine follows up venture round with pair of C-suite hires
Plus: Management changes at Cidara, Fujifilm Cellular Dynamics and Transneural
Read More
BioCentury
|
Apr 5, 2025
Discovery & Translation
Science Spotlight: A FOXP3 regulator to enhance induced Tregs
BioCentury’s roundup of translational innovations also includes insights into high-fat diet disruption of feeding motivation; ER-targeted antigens; and more
Read More
BioCentury
|
Mar 25, 2025
Management Tracks
Warp Speed veteran Hepburn named EVP of R&D at Panther
Plus: Elicio names Preetam Shah CFO and chief strategy officer, and updates from Halozyme, Newron and Skye
Read More
BioCentury
|
Feb 20, 2025
Management Tracks
Bourla becomes chair of PhRMA
Plus: Steve Worland named CEO of Atomwise and updates from Ona, Cidara and Biosion
Read More
BioCentury
|
Jan 11, 2025
Management Tracks
Faces in new places ahead of JPM: Rubin joining Guggenheim
Week’s management moves include new venture partners at Frazier and updates from Beigene, Intellia and more
Read More
BioCentury
|
Jan 9, 2025
Management Tracks
Bayer vet Moeller to lead Antag
Plus: CMO changes at Sunbird and Cidara, and updates from Aicuris, Renovaro, Noema and more
Read More
BioCentury
|
Nov 23, 2024
Finance
ATB’s €54M series A among largest ever in Belgium
BioCentury’s Financial Report also includes new biotech foundry Jupiter, and public equity fundings for Spyre, Cidara and Aclaris
Read More
BioCentury
|
Nov 20, 2024
Product Development
Biotechs now match pharma for FDA approvals
Half of FDA approvals are sponsored by biotechs; almost all are marketing in the U.S. themselves
Read More
BioCentury
|
Oct 19, 2024
Finance
Biotech restructurings show signs of slowing
Temporary respite or reflection of a stabilizing sector?
Read More
BioCentury
|
Aug 20, 2024
Management Tracks
Toraishi steps down from Rakuten Medical as co-CEO
Plus: SalioGen hired Kalliopi Stasi as CMO and updates from PepGen, Cidara and Bio-Rad
Read More
Items per page:
10
1 - 10 of 60